MedCap AB (CHIX:MCAPS) Moat Score: 0/10 (As of Jul. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:MCAPS MedCap AB CHIX:MCAPS
93 GF Score
Price kr555.00
GF Value kr596.05
Valuation Fairly Valued
View Full Analysis

What is MedCap AB Moat Score?

MedCap AB has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

MedCap AB has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes MedCap AB might have No Moat - No discernible moat.

MedCap AB  (CHIX:MCAPs) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

MedCap AB Moat Score Related Terms

CHIX:MCAPS
93GF Score
MedCap AB CHIX:MCAPS
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is MedCap AB (CHIX:MCAPS) Overvalued in 2026?

Based on GuruFocus' analysis, MedCap AB stock appears to be undervalued. The current stock price of kr555.00 is trading 6.9% below its estimated GF Value™ of kr596.05. GuruFocus considers MedCap AB to be Fairly Valued.

Key valuation signals for CHIX:MCAPS:

  • Moat Score: 0
  • GF Value™: kr596.05 vs. price of kr555.00 (6.9% below fair value)
  • GF Score™: 93/100

No single metric tells the full story. See the CHIX:MCAPS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MedCap AB Business Description

Other Exchanges MCAP:Sweden61MA:Germany
Address Sundbybergsvagen 1, Solna, SWE, 171 73
MedCap AB acquires and develops profitable, market-leading niche companies in the Nordic life science industry. It is diversified into two business areas namely Medical technology and Specialist medicines. Medical Technology mainly develops and sells various medical technology products and services. Its Specialist medicines develop and sell medicines within the regulatory classes of registered, extemporaneous and licensed medicines.
93GF Score

Get the complete analysis for CHIX:MCAPS

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr555.00
Price
kr596.05
GF Value